Pancreatic Cancer Research

ResearcherHarvard UniversityActive in the last 2 years

Edward E. Whang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2300-0647; OpenAlex author ID A5072328168. Sources: OpenAlex.

Their work

Papers
16 (first author 2, last author 12)
Trials
0
Grants
0
Labs led
1
Collaborators
11
Papers, trials and grants by year

2015: 2 papers · 2016: 1 paper · 2017: none · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: 7 papers · 2024: none · 2025: 6 papers

Papers 16

  1. Retraction Note: Overexpression of HMGA1 promotes anoikis resistance and constitutive Akt activation in pancreatic adenocarcinoma cells. Last author DOI 10.1038/s41416-025-03036-y↗
  2. Editor's Note: A Novel Role for Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6 as a Determinant of Gemcitabine Chemoresistance in Pancreatic Adenoca… Last author DOI 10.1158/0008-5472.can-25-0886↗
  3. Retraction: Prostaglandin E2 Enhances Pancreatic Cancer Invasiveness through an Ets-1-Dependent Induction of Matrix Metalloproteinase-2. Last author DOI 10.1158/0008-5472.can-25-0887↗
  4. Retraction: HMGA1 Is a Determinant of Cellular Invasiveness and In vivo Metastatic Potential in Pancreatic Adenocarcinoma. Last author DOI 10.1158/0008-5472.can-25-0888↗
  5. Editor's Note: HMGA1 Is a Molecular Determinant of Chemoresistance to Gemcitabine in Pancreatic Adenocarcinoma. First author DOI 10.1158/1078-0432.ccr-25-0819↗
  6. Editor's Note: RNA Interference Demonstrates a Novel Role for Integrin-Linked Kinase as a Determinant of Pancreatic Adenocarcinoma Cell Gemcitabine Chemoresist… Last author DOI 10.1158/1078-0432.ccr-25-0820↗
  7. Withdrawal: CEACAM6 cross-linking induces caveolin-1-dependent, Src-mediated focal adhesion kinase phosphorylation in BxPC3 pancreatic adenocarcinoma cells. Last author DOI 10.1016/j.jbc.2023.105007↗
  8. Retraction notice to Retrovirally mediated RNA interference targeting the M2 subunit of ribonucleotide reductase (RRM2): a novel therapeutic strategy in pancre… Last author DOI 10.1016/j.surg.2023.01.008↗
  9. Retraction notice to Glucose transporter-1 gene expression is associated with pancreatic cancer invasiveness and MMP-2 activity [Surgery -September 2004, Pages… Last author DOI 10.1016/j.surg.2023.01.009↗
  10. Retraction Note: CEACAM6 gene silencing impairs anoikis resistance and in vivo metastatic ability of pancreatic adenocarcinoma cells. Last author DOI 10.1038/s41388-023-02625-6↗
  11. Retraction Note: EphA2: a determinant of malignant cellular behavior and a potential therapeutic target in pancreatic adenocarcinoma. Last author DOI 10.1038/s41388-023-02626-5↗
  12. Retraction Note: RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine. Last author DOI 10.1038/s41388-023-02627-4↗
  13. Editorial Expression of Concern: Overexpression of CEACAM6 promotes insulin-like growth factor I-induced pancreatic adenocarcinoma cellular invasiveness. Last author DOI 10.1038/s41388-023-02784-6↗
  14. Associations of Socioeconomic Variables With Resection, Stage, and Survival in Patients With Early-Stage Pancreatic Cancer. Co-author DOI 10.1001/jamasurg.2015.4239↗
  15. Radiation therapy for unresectable pancreatic adenocarcinoma: population-based trends in utilization and survival rates in the United States. Co-author DOI 10.1001/jamasurg.2014.1837↗
  16. Efficacy of Neoadjuvant Versus Adjuvant Therapy for Resectable Pancreatic Adenocarcinoma: A Decision Analysis. First author DOI 10.1245/s10434-015-4711-0↗

Closest collaborators

The 11 strongest of 11 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Mark S. Duxbury · 10 shared papers, 2023–2025 · strength 2.54
  2. Stanley W. Ashley · 10 shared papers, 2023–2025 · strength 2.54
  3. Hiromichi Ito · 8 shared papers, 2015–2025 · strength 1.90
  4. Siong‐Seng Liau · 2 shared papers, 2025 · strength 0.96
  5. Hiromichi Ito · 3 shared papers, 2023 · strength 0.71
  6. S-S Liau · 1 shared paper, 2025 · strength 0.37
  7. Thomas E. Clancy · 1 shared paper, 2025 · strength 0.28
  8. Mia Shapiro · 2 shared papers, 2015–2016 · strength 0.12
  9. Jason S. Gold · 2 shared papers, 2015–2016 · strength 0.12
  10. Gaurav Sharma · 1 shared paper, 2015 · strength 0.07
  11. Naim U. Rashid · 1 shared paper, 2015 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.